Press releases
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
- Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 567.34 |
Average volume | -- |
---|---|
Shares outstanding | 354.36m |
Free float | 195.56m |
P/E (TTM) | 45.24 |
Market cap | 99.22bn SEK |
EPS (TTM) | 6.19 SEK |
Data delayed at least 20 minutes, as of Sep 07 2021 12:30 BST.
More ▼